Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.49 |
| ▸ | RORC | P51449 | 1/20 | 0.47 |
| ▸ | MEN1 | O00255 | 1/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.44 |
| ▸ | P2RX3 | P56373 | 3/20 | 0.43 |
| ▸ | LMNA | P02545 | 1/20 | 0.43 |
| ▸ | FPR2 | P25090 | 6/20 | 0.43 |
| ▸ | PROKR1 | Q8TCW9 | 6/20 | 0.43 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.42 |
| ▸ | POLB | P06746 | 1/20 | 0.42 |
| ▸ | EGFR | P00533 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.40 |
| ▸ | NPC1 | O15118 | 1/20 | 0.40 |
| ▸ | RAB9A | P51151 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5864995 | 0.90 | RORC (0.49) | RORCP2RX3LMNAFPR2PROKR1 | |
| SCHEMBL5865064 | 0.90 | RORC (0.48) | RORCP2RX3LMNAFPR2PROKR1 | |
| SCHEMBL5865179 | 0.89 | HRH1 (0.47) | RORCP2RX3POLBALDH1A1 | |
| SCHEMBL5864927 | 0.89 | RORC (0.50) | SMN1; SMN2RORCP2RX3LMNAL3MBTL1 | |
| SCHEMBL5865205 | 0.88 | RORC (0.47) | SMN1; SMN2RORCP2RX3LMNAL3MBTL1 | |
| SCHEMBL5864758 | 0.88 | RORC (0.47) | RORCMEN1KMT2AP2RX3 | |
| SCHEMBL5864754 | 0.87 | KDM4E (0.49) | RORCKMT2AP2RX3LMNAL3MBTL1 | |
| SCHEMBL5864748 | 0.86 | RORC (0.45) | SMN1; SMN2RORCP2RX3LMNA | |
| SCHEMBL5864923 | 0.86 | RORC (0.45) | RORCP2RX3LMNA | |
| SCHEMBL5865143 | 0.85 | SCN8A (0.50) | RORCP2RX3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7030138-B2 | Benzamidine derivatives | SANKYO COMPANY, LIMITED (JP) | 2006-04-18 | — | — | US | disclosed |
| US-20040147555-A1 | Benzamidine derivatives | SANKYO COMPANY, LIMITED (JP) | 2004-07-29 | — | — | US | disclosed |
| EP-1375482-A1 | BENZAMIDINE DERIVATIVE | Sankyo Company, Limited (JP) | 2004-01-02 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040147555-A1 | Benzamidine derivatives | F9, F7, F2 | SMN1; SMN2 4174/4885RORC 4836/4885MEN1 2403/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.